GlassScriptPhysician profile
Channing C Broyan
NPI 1952719205
$8,802.61
in general payments reported to CMS, 2019-2025
33 companies · $1,764 in 2025
The $1,764 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,165 · 2022: $2,513 · 2023: $1,967 · 2024: $1,394 · 2025: $1,764.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,842 · Education: $283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,841.72 |
| Education | $282.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,523.02 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $963.74 | 2022-2025 | Ilumya, Winlevi, Absorica Ld |
| Regeneron Healthcare Solutions, INC. | $717.27 | 2021-2025 | Dupixent |
| Lilly USA, LLC | $697.66 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Janssen Biotech, INC. | $684.29 | 2022-2024 | Tremfya |
| Incyte Corporation | $681.03 | 2021-2025 | Opzelura |
| Hill Dermaceuticals, INC. | $336.19 | 2025 | Tolak |
| Pfizer INC. | $327.46 | 2022-2023 | |
| Genzyme Corporation | $304.22 | 2022-2024 | |
| Teva Pharmaceuticals USA, INC. | $234.74 | 2021-2022 | |
| Leo Pharma INC. | $216.75 | 2022-2025 | Adbry |
| Amgen INC. | $215.80 | 2021-2022 | |
| Arcutis Biotherapeutics, INC. | $205.71 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $198.39 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $196.18 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $178.82 | 2023-2025 | Bimzelx, Cimzia |
| Horizon Therapeutics Plc | $176.46 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $139.47 | 2023-2025 | Sotyktu |
| Janssen Scientific Affairs, LLC | $124.97 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $123.51 | 2024 | Caplyta |
| Biohaven Pharmaceuticals, INC. | $115.29 | 2021 | |
| Sanofi-Aventis U.S. LLC | $79.99 | 2022 | |
| Almirall LLC | $76.95 | 2023 | Klisyri |
| Galderma Laboratories, L.P. | $55.68 | 2022-2025 | Aklief, Nemluvio |
| Dermavant Sciences, INC. | $50.33 | 2023-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $41.74 | 2023-2025 | Arazlo, Jublia, Cabtreo |
| Genentech USA, INC. | $35.72 | 2021-2023 | Xolair |
| Sebela Pharmaceuticals INC. | $19.40 | 2023 | Naftin |
| Organon LLC | $18.24 | 2025 | |
| Journey Medical Corporation | $17.79 | 2022 | |
| Verrica Pharmaceuticals INC. | $15.87 | 2025 | Ycanth |
| Karyopharm Therapeutics INC. | $15.40 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.53 | 2024 | Cyltezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Channing Broyan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.